NCT05233163View on ClinicalTrials.gov

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
Transthyretin Amyloid Cardiomyopathy
Interventions
DRUG

Empagliflozin

Empagliflozin 10 mg oral daily for 12 weeks

Trial Locations (1)

10032

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York

All Listed Sponsors
lead

Columbia University

OTHER